8398 related articles for article (PubMed ID: 21428850)
1. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
3. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
[TBL] [Abstract][Full Text] [Related]
4. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
Shah P; Forget MA; Frank ML; Jiang P; Sakellariou-Thompson D; Federico L; Khairullah R; Neutzler CA; Wistuba I; Chow CB; Long Y; Fujimoto J; Lin SY; Maitra A; Negrao MV; Mitchell KG; Weissferdt A; Vaporciyan AA; Cascone T; Roth JA; Zhang J; Sepesi B; Gibbons DL; Heymach JV; Haymaker CL; McGrail DJ; Reuben A; Bernatchez C
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110355
[TBL] [Abstract][Full Text] [Related]
5. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
6. Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy.
Choi S; Hossain M; Lee H; Baek J; Park HS; Lim CL; Han D; Park T; Kim JH; Gong G; Kweon MN; Lee HJ
Cancer Immunol Immunother; 2024 Apr; 73(6):101. PubMed ID: 38630265
[TBL] [Abstract][Full Text] [Related]
7. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.
Dudley ME; Wunderlich JR; Shelton TE; Even J; Rosenberg SA
J Immunother; 2003; 26(4):332-42. PubMed ID: 12843795
[TBL] [Abstract][Full Text] [Related]
8. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
Schiltz PM; Beutel LD; Nayak SK; Dillman RO
J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
[TBL] [Abstract][Full Text] [Related]
9. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
10. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck.
Hald J; Rasmussen N; Claesson MH
Cancer Immunol Immunother; 1995 Oct; 41(4):243-50. PubMed ID: 7489567
[TBL] [Abstract][Full Text] [Related]
11. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
[TBL] [Abstract][Full Text] [Related]
12. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
Prieto PA; Durflinger KH; Wunderlich JR; Rosenberg SA; Dudley ME
J Immunother; 2010 Jun; 33(5):547-56. PubMed ID: 20463593
[TBL] [Abstract][Full Text] [Related]
13. Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures.
Junker N; Kvistborg P; Køllgaard T; Straten Pt; Andersen MH; Svane IM
Cell Immunol; 2012; 273(1):1-9. PubMed ID: 22230732
[TBL] [Abstract][Full Text] [Related]
14. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
15. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
16. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
Mulder WM; Stukart MJ; Roos M; van Lier RA; Wagstaff J; Scheper RJ; Bloemena E
Cancer Immunol Immunother; 1995 Nov; 41(5):293-301. PubMed ID: 8536275
[TBL] [Abstract][Full Text] [Related]
17. IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma.
Melief SM; Visser M; van der Burg SH; Verdegaal EME
Cancer Immunol Immunother; 2017 Jul; 66(7):913-926. PubMed ID: 28401257
[TBL] [Abstract][Full Text] [Related]
18. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
20. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
